Litcius/Paper detail

Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial

Shunya Ikeda, Masatoshi Kudo, Namiki Izumi, Masahiro Kobayashi, Mie Azuma, Genevieve Meier, Janice Pan, Mika Ishii, Shuichi Kaneko

2021Value in Health Regional Issues15 citationsDOI

Topics & Concepts

LenvatinibHepatocellular carcinomaMedicineInternal medicineOncologySorafenibHepatocellular Carcinoma Treatment and PrognosisEconomic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of Life
Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial | Litcius